Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 10—October 2024
Research

Economic Analysis of National Program for Hepatitis C Elimination, Israel, 20231

Yuval DadonComments to Author , Francis B. Mimouni, Ariella Toren, Tal Morgenstern, Lior Barak, and Joseph Mendlovic
Author affiliations: Ministry of Health, Jerusalem, Israel (Y. Dadon, A. Toren, T. Morgenstern, L. Barak, J. Mendlovic); Leumit Health Care, Tel Aviv, Israel (F.B. Mimouni); Sackler School of Medicine, Tel Aviv (F.B. Mimouni); Shaare Zedek Medical Center, Hadassah-Hebrew University School of Medicine, Jerusalem, Israel (J. Mendlovic)

Main Article

Figure 2

Flowchart of participant enrollment, virologic screening, and HCV treatment in an economic analysis of a national program for hepatitis C elimination, Israel, 2023. HCV, hepatitis C virus.

Figure 2. Flowchart of participant enrollment, virologic screening, and HCV treatment in an economic analysis of a national program for hepatitis C elimination, Israel, 2023. HCV, hepatitis C virus.

Main Article

1Preliminary results from this study were presented at the Israel National Institute for Health Policy Research conference; May 31, 2023; Tel Aviv, Israel.

Page created: August 21, 2024
Page updated: September 17, 2024
Page reviewed: September 17, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external